Skip to main content

Table 3 Most prominent altered genes after in vitro interventions of human transformed germinal centre B cells investigated in gene expression profiles of primary samples of aggressive Non-Hodgkin Lymphoma

From: Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas

 

BAFF

 

CD40L

 

anti-IgM

 

IL21

 

LPS

 
 

Gene symbols

log2FC

Gene symbols

log2FC

Gene symbols

log2FC

Gene symbols

log2FC

Gene symbols

log2FC

1

ID1

−2,07

ID1

−2,007

CYP26A1

−2,752

BCL6

−1,904

ID1

−1,9

2

ID4

−0,92

C3orf37

−1,432

ID4

−2,687

SOX2*

−1,805

RGS18*

−0,853

3

BNIP3

−0,79

SMAD1*

−1,182

BEST3*

−2,41

DNAJB4

−1,589

C3orf37

−0,85

4

TXNIP

−0,74

DEPTOR

−1,159

IL7R*

−2,399

ID3

−1,534

DDIT4

−0,83

5

BNIP3L

−0,72

CAB39L

−1,086

BMP7

−2,373

DDIT4

−1,514

ID3

−0,811

6

PFKFB4*

−0,71

CD83

−1,017

SOX4

−2,343

ID1

−1,493

METTL7A

−0,8

7

GPER

−0,68

METTL7A

−1,005

TNFSF8*

−2,264

RGCC

−1,239

CAB39L*

−0,799

8

PNOC

−0,67

ANKRD36BP2*

−0,983

RNF144B*

−2,213

IL7R

−1,152

TXNIP

−0,786

9

RGS18*

−0,66

ID3

−0,983

DNAJB4

−2,156

HEY2*

−1,136

BNIP3

−0,776

10

P4HA1

−0,654

ENPP3*

−0,937

ID1

−2,093

VEGFA

−1,115

ID4

−0,776

11

CCNG2

−0,635

IRF8

−0,924

BCL6

−2,037

GADD45A

−0,982

CCNG2

−0,721

12

HILPDA

−0,631

RGS18*

−0,919

RHOH

−2,005

CYTIP

−0,93

PFKFB4*

−0,709

13

ID2

−0,585

FAM167A*

−0,909

RGCC

−1,946

PCDH9

−0,914

KDM3A

−0,69

14

SAMD13*

−0,582

AICDA

−0,864

NCKAP1

−1,857

CCNG2

−0,889

HILPDA*

−0,678

15

CD24

−0,578

GPER

−0,852

IKZF1*

−1,845

TXNIP

−0,872

FAM167A*

−0,673

16

ID3

−0,564

ID4

−0,835

HEY2*

−1,761

BICD2

−0,868

PTPRC

−0,665

17

C3orf37

−0,56

PDZRN4

−0,809

PCDH9

−1,751

RGS18*

−0,861

STAT2*

−0,649

18

GPR18

−0,541

BNIP3

−0,785

SOX2*

−1,723

ANKRD37*

−0,852

SAMD13*

−0,631

19

ALDOC

−0,516

VEGFA

−0,777

MYCT1*

−1,716

TRIM8

−0,836

ENPP3*

−0,609

20

BBOX1

−0,516

TP53INP1*

−0,776

RGS18*

−1,715

KIAA0907

−0,786

SMAD1*

−0,593

21

CD83

−0,509

PTPRC

−0,77

SMAD1

−1,679

NEDD9

0,787

P4HA1

−0,593

22

POLD4

−0,494

RASSF6*

−0,767

MLLT3

−1,656

RELB

0,79

VEGFA

−0,592

23

HBP1

−0,484

CCNG2

−0,761

KIF20A

−1,631

PAPD5*

0,791

KLRC3

−0,591

24

FAM167A*

−0,476

CLEC2B

−0,74

FAM214A*

−1,612

ZNFX1*

0,794

GPER

−0,588

25

EVI2A

−0,476

BMP7

−0,735

BCL2

1,618

B3GNT2*

0,797

ZNF385B*

−0,588

26

TP53INP1*

−0,474

TLR1

−0,732

PSAT1*

1,62

HIF1A

0,814

TP53INP1*

−0,583

27

YPEL5

−0,467

SATB1

−0,731

LOC285628*

1,637

KIF26B

0,814

UBE2H*

−0,581

28

TRIM22

−0,464

BTG2

−0,726

FAIM3

1,641

MMD

0,82

TRIM22

−0,571

29

TLR1

−0,463

PCDH9

−0,725

MAP2K3

1,644

AICDA*

0,822

PIK3C2B

−0,571

30

CLEC2B

−0,463

PRKACB

−0,724

PPP1R15A

1,662

EPSTI1*

0,837

STAP1

−0,564

31

HLA-C

0,457

GPM6A

−0,721

FAM208B

1,674

RAB11FIP1

0,844

BNIP3L

−0,558

32

ACTR3*

0,46

STAT2*

−0,72

SIAH2

1,676

RAB30

0,845

MYBL1

−0,556

33

NAF1*

0,46

CLIP2

0,721

HIVEP3*

1,679

SIN3A*

0,847

GPM6A

−0,549

34

PSMD12

0,461

ARHGAP17

0,727

METRNL*

1,711

PLEK

0,854

ANKRD37*

−0,548

35

NUDT5*

0,461

CFLAR

0,74

HERPUD1

1,727

IFITM1

0,863

SPG11

−0,537

36

TESC

0,463

FYTTD1*

0,743

KLF10

1,749

PRDM2

0,885

NARF

−0,536

37

CCAR1*

0,464

HLA-DMB

0,747

LTA

1,753

DUSP10

0,888

ABCA1

−0,531

38

ANKRD33B*

0,465

MTMR10*

0,749

GPR18

1,769

FAM100B*

0,892

SEC14L1

−0,531

39

RILPL2*

0,466

HLA-F

0,754

IFRD1

1,777

FAS

0,894

IL7R

−0,522

40

PLCB1

0,467

PLEK

0,757

CD274*

1,785

IL7

0,896

H1FX

−0,52

41

NFKBIE

0,47

PPP1R9B*

0,759

SLC3A2

1,79

CD69

0,921

ASF1A

−0,511

42

DDX21

0,47

TESC

0,764

HSPA5

1,8

B4GALT1*

0,923

GLCCI1*

−0,509

43

TAPBP

0,471

IGLL1

0,765

ATF3

1,834

BCL2L1

0,924

EVI2A

−0,508

44

RBBP6

0,474

SNX20*

0,765

DENND4A

1,848

CD40

0,934

VGLL4

−0,507

45

SOGA2

0,474

CREM*

0,77

ARHGAP25

1,849

TET3*

0,951

PRKACB

−0,503

46

HINT1*

0,474

IKBKE

0,782

TOR3A

1,85

SOCS1

0,962

LRP4

−0,499

47

SRRM1

0,475

FAS

0,788

IRF2BP2*

1,868

NFKBID*

0,983

PLCXD1

−0,498

48

PHACTR4

0,475

CIITA

0,788

SLC30A1

1,886

SRSF5

0,996

CLEC2B

−0,497

49

AK3*

0,476

TAP1

0,789

TNF

1,905

MASTL*

1,011

LOC440864*

−0,494

50

KPNB1

0,477

NOTCH2NL*

0,797

CTH

1,91

TLR7

1,036

SLC44A1*

−0,493

51

GTF2H2B*

0,477

RFX5

0,806

APOBEC3B

1,928

MCL1

1,04

TSPAN11*

−0,484

52

TAF1D

0,477

FDXR

0,81

NFKB1

1,94

PIM2

1,06

BTN2A2

0,488

53

CSF2RB

0,479

NFKBIE

0,827

CD58

1,946

IER2

1,067

NFKBIE

0,493

54

MYBBP1A

0,481

MIR155HG*

0,829

NFKBIE

1,958

ZFP36L1

1,072

HLA-C

0,495

55

YY1*

0,483

LOXL2

0,829

NAB2

1,984

IFIT2*

1,072

LSS

0,502

56

FLVCR1*

0,488

HLA-B

0,831

JUND

2,024

SNX11

1,078

FDXR

0,502

57

NAA16

0,49

VAV2*

0,832

ARL4C

2,026

TAP1

1,086

KLHDC5*

0,505

58

SRRT

0,491

ZNF385C*

0,836

UPP1

2,029

JUNB

1,088

HLA-B

0,511

59

TNRC6A*

0,493

RASSF2

0,841

CDKN1A

2,033

LRRC32

1,1

CCDC28B

0,514

60

FNBP1

0,494

HLA-E

0,843

FAM100B*

2,059

NA

1,101

HLA-DMB

0,517

61

CIZ1

0,495

BIRC3

0,845

MDFIC

2,091

MARCKS

1,108

CUX2

0,519

62

TOMM40

0,495

ANKRD33B*

0,847

IER2

2,137

DUSP2

1,134

DUSP22*

0,523

63

TBC1D24*

0,498

ANXA7

0,85

DUSP10

2,144

NUDT4

1,139

RPS6KA1

0,527

64

ILF3

0,498

HVCN1*

0,85

FAM102A

2,198

CXCR5

1,155

HLA-DOA*

0,527

65

NFKB2

0,501

EPB41L4B*

0,86

RAB8B*

2,198

IER5

1,155

SYNCRIP

0,528

66

TFDP1*

0,505

PIK3CD

0,864

PTGER4

2,204

BCL3

1,16

ZNF385C*

0,533

67

ZNF385C*

0,508

LAT2

0,871

HLA-DQB1

2,206

SAMSN1

1,18

DENND4A

0,535

68

LYAR*

0,508

HCP5

0,884

ARAP2

2,214

NFKBIZ*

1,2

PDLIM3*

0,535

69

BIRC3

0,508

HLA-DOA*

0,894

SLC7A11

2,215

IL2RA

1,211

FYTTD1*

0,536

70

LRP8

0,513

SYNGR2

0,901

MIR155HG*

2,249

PARP9*

1,212

ELL2*

0,537

71

CCDC28B

0,514

ALCAM

0,905

CD69

2,278

USP18

1,229

HLA-E

0,539

72

C8orf12*

0,514

WNT5A

0,916

TSC22D3

2,287

MAP3K8

1,333

IRF2BP2*

0,539

73

HLA-B

0,519

RUNX3

0,932

RGS16

2,316

ZC3H12A

1,38

DNAJB1

0,54

74

HSP90B1

0,523

BMP2K*

0,935

ZFP36L1

2,331

NFKBIA

1,435

IGLL1

0,545

75

KLHDC5*

0,525

CTSH

0,935

TRIB3

2,354

RGS16

1,437

TFDP1*

0,558

76

RP9*

0,526

PLEKHO1

0,94

IL21R*

2,373

GADD45B

1,481

PSPC1*

0,56

77

PEA15

0,528

RPS6KA1

0,956

KLF6*

2,383

MIR155HG*

1,498

ANKRD33B*

0,562

78

MT1X

0,534

DUSP22

0,963

PHACTR1

2,423

LINC00158*

1,525

CREBZF

0,565

79

MAN1A1

0,539

IFIH1

0,991

SESN2*

2,446

PTGER4

1,563

IRF4

0,575

80

DNAJB1

0,543

OLFML2A

0,994

TNFAIP3

2,612

DTX3L*

1,58

C8orf12*

0,579

81

SOGA1*

0,554

HLA-DQB1

0,994

CD1C

2,662

CXCL10

1,616

FNBP1

0,617

82

CENPV*

0,555

COL1A1*

1,003

PLEK

2,716

TNFAIP3

1,636

ANXA7

0,641

83

ICAM1

0,567

ICAM1

1,006

FAM46C*

2,926

MX1

1,638

MT1X

0,67

84

CD58

0,568

NFKB2

1,009

CD83

2,973

STAT1

1,659

BATF

0,702

85

NCOR2

0,578

NEIL2*

1,021

DDIT3

2,977

BIRC3

1,66

CALR

0,703

86

SNHG12*

0,585

FNBP1

1,041

DUSP2

3,004

EGR2

1,69

HLA-DQA1*

0,706

87

SLC23A2

0,586

BATF

1,061

SQSTM1

3,036

NFKBIE

1,765

OLFML2A

0,714

88

OLFML2A

0,588

CCDC28B

1,066

PHLDA1

3,048

IFIT5

1,913

UMODL1*

0,716

89

LRRFIP1

0,59

MAN1A1

1,082

BHLHE40

3,141

BCL2A1

1,942

HLA-DQB1

0,723

90

DENND4A

0,599

CUX2

1,089

SLAMF7*

3,147

IRF1

1,965

IKBKE

0,723

91

IGLL1

0,614

HLA-DQA1*

1,092

CCR7

3,572

SLC30A1

1,969

NEIL2*

0,726

92

OVOS2*

0,63

DENND4A

1,101

NA*

3,693

IFIT3*

1,973

RILPL2*

0,779

93

C1orf63

0,649

HLA-DPA1

1,105

LINC00158*

3,798

IRF4

2,167

MAN1A1

0,781

94

EIF5B

0,681

RILPL2*

1,117

LY9*

4,131

IFIT1

2,186

CREM

0,795

95

RUNX3

0,702

DOCK10

1,202

EGR1*

4,232

CMPK2*

2,253

HLA-DPA1

0,816

96

NA

0,704

BTN2A2

1,254

BCL2A1

4,295

BATF

2,3

ACTR3*

0,833

97

HLA-DQB1

0,726

NA

1,262

EGR2

4,518

CD83

2,705

CD58

0,834

98

HLA-DQA1

0,731

ELL2*

1,467

SGK1

4,84

SGK1

2,798

NA

0,952

99

TCOF1

0,744

CD58

1,62

DUSP5

5,011

ICAM1

2,918

LINC00158*

0,954

100

ELL2*

0,747

LINC00158*

1,793

RGS1

5,476

IRF9

3,155

IFIT3*

1,051

  1. Two independent patients cohort were tested. The gene expression from 219 primary lymphoma samples described by Hummel et al. (MMML-1 cohort) and 99 primary lymphoma samples published by Dave et al. (LLMPP-cohort) were compared to global gene expression changes described within the text [20, 21]. The deviation from the TOP100 LIMMA gene lists from in vitro interventions is determined by the absence of hybridization probes on the microarrays used for lymphoma gene expression description. In addition multiple hybridization probes for one gene were condensed into a single event.